GlassScriptPhysician profile
Leyla I Somen
NPI 1285788075
$7,215.08
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $1,260 · 2021: $1,646 · 2022: $1,562 · 2023: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,641.90 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,169.43 | 2019-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Allergan, INC. | $672.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $516.28 | 2019-2023 | Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $381.23 | 2020-2022 | |
| Lundbeck LLC | $377.23 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $321.30 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $317.58 | 2019-2023 | Ingrezza |
| Alkermes, INC. | $265.24 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.74 | 2019-2023 | Trintellix |
| Corium, LLC | $188.92 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $146.46 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $131.67 | 2019-2023 | Spravato |
| Jazz Pharmaceuticals INC. | $122.84 | 2019-2021 | |
| Eisai INC. | $118.36 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $117.05 | 2019-2022 | |
| Indivior INC. | $84.46 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $79.14 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $64.27 | 2019 | |
| Avanir Pharmaceuticals, INC. | $63.42 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $59.99 | 2022-2023 | Qelbree |
| Axsome Therapeutics, INC. | $31.58 | 2023 | Auvelity |
| Bausch Health US, LLC | $20.06 | 2022 | |
| Noven Therapeutics, LLC | $19.41 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.48 | 2019 | |
| Owp Pharmaceuticals, INC. | $14.97 | 2022 | |
| Shire North American Group INC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leyla Somen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.